References
- Kanis J, Melton J, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res 1994; 9: 1137–1141
- Lindsay R, Aitken J, Anderson J, et al. Long-term prevention of postmenopausal osteoporosis by oestrogen. Lancet 1976; 1: 1038–1041
- Torgerson D, Bell-Syer S. Hormone replacement therapy and prevention of nonvertebral fractures. JAMA 2001; 285: 2891–2897
- Haarbo J, Hassager C, Signe B, et al. Serum lipids, lipoproteins, and apolipoproteins during postmenopausal estrogen replacement therapy combined with either 19-nortestosterone derivatives or 17-hydroxyprogesterone derivatives. Am J Med 1991; 90: 584–589
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288: 321–333
- Tanko L B, Bruun J M, Alexandersen P, et al. Novel associations between bioavailable estradiol and adipokines in elderly women with different phenotypes of obesity: implications for atherogenesis. Circulation 2004; 110: 2246–2252
- Samsioe G. HRT and cardiovascular disease. Ann N Y Acad Sci 2003; 997: 358–372
- Christiansen C. Effects of drospirenone/estrogen combinations on bone metabolism. Presented at a Schering AG sponsored symposium, Drospirenone: more than a progestogen!, at the International Society of Gynecological Endocrinology (ISGE). FlorenceItaly 2004
- Barrett-Connor E. The economic and human costs of osteoporotic fracture. Am J Med 1995; 98: 3S–8S
- Bagger Y, Tanko L, Alexandersen P, et al. Two to three years of hormone replacement treatment in healthy women have long-term preventative effects on bone mass and osteoporotic fractures: the PERF study. Bone 2004; 3: 728–735
- Bagger Y, Tanko L, Alexandersen P, et al. Early postmenopausal hormone replacement therapy may prevent cognitive impairment later in life. Menopause 2005; 12: 12–17
- Marsh M, Crook D, Whitcroft S, et al. Effect of continuous combined estrogen and desogestrel hormone replacement therapy on serum lipids and lipoproteins. Obstet Gynecol 1994; 83: 19–23
- Ketola E, Siplia R, Makela M. Effectiveness of individual lifestyle interventions in reducing cardiovascular disease and risk factors. Ann Med 2000; 32: 239–251
- Teichmann A. Pharmacology of estradiol valerate/dienogest. Climacteric 2003; 6(Suppl 2)17–23
- Mansour D. Yasmin – a new oral contraceptive, a new progestogen: the reasons why. Eur J Contracept Reprod Health Care 2000; 5(Suppl 3)9–16
- Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000; 62: 29–38
- Rubig A. Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties. Climacteric 2003; 6(Suppl 3)49–54
- Warming l, Ravn P, Nielsen T, Christiansen C. Safety and efficacy of drospirenone used in a continuous combination with 17β-estradiol for prevention of postmenopausal osteoporosis. Climacteric 2004; 7: 103–111